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deciphering Gene Expression
rofiling in Cardiac
esynchronization Therapy
e read with interest the article by Vanderheyden et al. (1). We
pplaud the authors for an ambitious study and the first report of
ene expression in human cardiac resynchronization therapy. The
imitations of the work were elucidated by both the authors and the
ditorial commentator (2). However, we have questions about
everal aspects of the article concerning both the functional as well
s the gene expression measurements that make interpretation of
he work problematic.
First, the magnitude of the effect of cardiac resynchronization
herapy in all patients (Table 3 in Vanderheyden et al. [1]) and
esponders (Table 4 in Vanderheyden et al. [1]) is quite striking.
ore disturbing, however, is that the magnitude of the beneficial
esponse, on average, was greater in the overall group than in the
ubset of responders. This result was true for ejection fraction
EF), left ventricular (LV) end-diastolic volume, several measures
f dyssynchrony, and phospholamban.
Some, but not all, of these differences may be accounted for by
aseline differences between responders and nonresponders, which
aises other issues regarding the findings. However, it is difficult to
magine how the overall increase in EF exceeds that in the
esponder group despite the similarity in baseline EF in both
esponders and nonresponders. The same is true of the decrement
n LV end-diastolic volume.
Finally, the definition of responders raises some questions.
here are clear differences in estimates of improvement in LV
jection fraction and changes in chamber size in the 2 groups, but
here is also evidence for mechanical synchronization of LV,
nterventricular, and atrioventricular contraction in both groups.
hus, the mechanism of clinical improvement likely involves more
han simple mechanical resynchronization, and the gene expres-
ion signature is likely a manifestation of more than resynchroni-
ation alone.
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e thank Dr. Aiba and colleagues for discussing the pivotal
ndings described in our article (1) with regards to the effects of
hronic cardiac resynchronization therapy (CRT) on myocardial
ene expression. They question the magnitude of the effect of
RT in our study. The effect in responders is indeed robust and
ay be related to the prudent definition of responders. In fact,
atients were categorized as responders only if they exhibited a
elative increase in left ventricular ejection fraction (LVEF) of
25% together with an improvement in New York Heart Asso-
iation functional class score 1 (2). This categorization may
ccount for the rather large improvements in LVEF and left
entricular (LV) dimensions compared with other studies that did
ot include both reverse remodeling and clinical improvement as
n indicator of response.
We acknowledge their concern about the paradoxically greater
hange in ejection fraction as well as in end-diastolic volumes in
he whole study population compared with the responders group.
fter reviewing the data, we noticed typing errors in Table 3 of our
rticle (1) that were responsible for the concern. The individual
VEF and end-diastolic volume at baseline and follow-up in all
atients, responders, and nonresponders are summarized in Figure
. In the whole study population, LV end-diastolic volume and
jection fraction at follow-up were 215  20 ml and 31  3%,
espectively. This error is truly regretful, and we apologize.
evertheless, we would like to point out that the error does not
lter the data on the functional or molecular comparisons between
he responders and nonresponders. In this regard, we respectfully
oint out that the magnitude of specific changes in LV dyssyn-
hrony and phospholamban as being reported in the entire
opulation is not greater than in any subgroup.
A recent study also corroborated our finding that mechanical
yssynchrony itself might not favorable predict a successful re-
ponse to CRT, but merely acts as an indicator for the presence of
hemodynamic reserve” in the setting of advanced heart failure (3).
herefore, less mechanical dyssynchrony, as evidenced in the non-
esponders in our study, would indicate a more advanced degree of
yocardial remodeling, less prone to favorably respond to CRT.
In addition, the paradox between the CRT effect on mechanical
esynchronization and different impact on LV remodeling and
unction in responder versus nonresponder groups has been de-
cribed previously (4). Similarly in the current study, although
nterventricular dyssynchrony decreased in both groups, baseline
ntraventricular LV dyssynchrony was greater in responders and
ecreased only in this group. This observation supports the
ypothesis that although mechanical resynchronization may be
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September 30, 2008:1177–8equired to reverse chamber dilation, the extent of the resynchro-
ization alone does not always correlate with the therapeutic effect
5). Other contributing factors may be related to underlying
isease, fibrosis, scar tissue, or the severity of molecular abnormal-
ties governing excitation-contraction coupling (1,6). Therefore, it
s interesting to emphasize that nonresponders had a greater
aseline gene expression of  and / major histocompatibility
omplex ratio as well as a trend toward greater gene expression of
arcoendoplasmatic reticulum Ca2 ATPase. Thus, despite a
imilar degree of LV dysfunction, dyssynchrony, and clinical heart
ailure class, and a comparable extent of resynchronization, non-
esponders were deemed “less sick” in terms of “molecular remod-
ling” and less likely to be responsive to CRT therapy. We do
cknowledge this to be a provocative hypothesis; it obviously
equires prospective validation in a larger cohort of patients in
ddition to the application of a more comprehensive assessment of
ranscriptional and translational changes before and after CRT.
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